HK1109409A1 - Antibodies directed to angiopoietin-2 and uses thereof - Google Patents

Antibodies directed to angiopoietin-2 and uses thereof

Info

Publication number
HK1109409A1
HK1109409A1 HK08103398A HK08103398A HK1109409A1 HK 1109409 A1 HK1109409 A1 HK 1109409A1 HK 08103398 A HK08103398 A HK 08103398A HK 08103398 A HK08103398 A HK 08103398A HK 1109409 A1 HK1109409 A1 HK 1109409A1
Authority
HK
Hong Kong
Prior art keywords
angiopoietin
antibodies directed
antibodies
directed
Prior art date
Application number
HK08103398A
Other languages
English (en)
Inventor
Larry L Green
Qing Zhou
Bruce A Keyt
Xiao-Dong Yang
Stephen Charles Emery
David C Blakey
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36405885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1109409(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1109409A1 publication Critical patent/HK1109409A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
HK08103398A 2004-12-21 2008-03-26 Antibodies directed to angiopoietin-2 and uses thereof HK1109409A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63835404P 2004-12-21 2004-12-21
US71128905P 2005-08-25 2005-08-25
PCT/US2005/045657 WO2006068953A2 (fr) 2004-12-21 2005-12-19 Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations

Publications (1)

Publication Number Publication Date
HK1109409A1 true HK1109409A1 (en) 2008-06-06

Family

ID=36405885

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08103398A HK1109409A1 (en) 2004-12-21 2008-03-26 Antibodies directed to angiopoietin-2 and uses thereof
HK16105651.1A HK1217713A1 (zh) 2004-12-21 2016-05-17 血管生成素- 的抗體及其應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16105651.1A HK1217713A1 (zh) 2004-12-21 2016-05-17 血管生成素- 的抗體及其應用

Country Status (27)

Country Link
US (5) US7973140B2 (fr)
EP (3) EP3699191A1 (fr)
JP (2) JP4884395B2 (fr)
KR (1) KR101017301B1 (fr)
CN (2) CN105085678B (fr)
AR (1) AR052065A1 (fr)
AT (1) ATE521638T1 (fr)
AU (1) AU2005319382B2 (fr)
BR (1) BRPI0519596B1 (fr)
CA (1) CA2595610C (fr)
CY (1) CY1112909T1 (fr)
DK (1) DK1838733T3 (fr)
ES (1) ES2371083T3 (fr)
HK (2) HK1109409A1 (fr)
HR (1) HRP20110859T1 (fr)
MX (1) MX2007007484A (fr)
NO (1) NO20073192L (fr)
NZ (1) NZ556029A (fr)
PL (1) PL1838733T3 (fr)
PT (1) PT1838733E (fr)
RS (1) RS52036B (fr)
RU (1) RU2394839C2 (fr)
SI (1) SI1838733T1 (fr)
TW (1) TW200634027A (fr)
UY (1) UY29288A1 (fr)
WO (1) WO2006068953A2 (fr)
ZA (1) ZA200705695B (fr)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003533187A (ja) * 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
EP2395016A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CN101370519B (zh) * 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
JP2010515717A (ja) * 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
SG187477A1 (en) * 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
US20110008804A1 (en) * 2007-11-05 2011-01-13 Kain Kevin C Angiopoietin-1 and -2 biomarkers for infectious diseases that compromise endothelial integrity
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
ES2689274T3 (es) 2008-01-03 2018-11-13 The Scripps Research Institute Dirección de anticuerpos mediante un dominio de reconocimiento modular
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CA2712000A1 (fr) * 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilises contre l'angiopoietine-2 et leurs utilisations
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2722466A1 (fr) 2008-04-29 2009-11-05 Tariq Ghayur Immunoglobulines a double domaine variable et utilisations
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
CA2729012A1 (fr) 2008-06-27 2009-12-30 Amgen Inc. Inhibition de l'ang-2 pour traiter la sclerose en plaques
WO2010006060A2 (fr) 2008-07-08 2010-01-14 Abbott Laboratories Immunoglobulines à double domaine variable de prostaglandine e2 et leurs utilisations
AU2013202410B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neautralizing antibodies and use thereof
PE20141432A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
CA2732003A1 (fr) 2008-07-31 2010-02-04 James D. Marks Anticorps neutralisant des neurotoxines botuliniques
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AU2016244220B2 (en) * 2008-12-23 2018-05-17 Amgen Inc. Human CGRP receptor binding proteins
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2385763B1 (fr) * 2009-01-12 2018-04-18 Aerpio Therapeutics, Inc. Méthodes de traitement du syndrome de fuite vasculaire
MX2011009798A (es) 2009-03-20 2011-12-08 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
WO2010129609A2 (fr) * 2009-05-07 2010-11-11 The Regents Of The University Of California Anticorps et procédés d'utilisation de ceux-ci
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PE20121494A1 (es) 2009-06-18 2012-11-01 Pfizer Anticuerpos anti notch-1
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CA2781519A1 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes proteiques contenant une super-helice et/ou une attache et leurs utilisations
WO2011038139A1 (fr) 2009-09-23 2011-03-31 Amgen Inc. Traitement du cancer de l'ovaire au moyen d'un agent de liaison spécifique de l'angiopoïétine-2 humaine en association avec un taxane
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2774032C (fr) * 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Molecules d'anticorps anti-gcc, compositions et procedes apparentes
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
KR101688522B1 (ko) * 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
CN101863980B (zh) * 2009-12-31 2013-05-08 中国药科大学 全人源抗血管内皮细胞生长因子受体2单链抗体
US20110171231A1 (en) * 2010-01-12 2011-07-14 Carlos Bais ANTI-PlGF ANTIBODIES AND METHODS USING SAME
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012009790A1 (fr) * 2010-07-22 2012-01-26 Schrader John W Protection croisée contre un pathogène, méthodes et compositions afférentes
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
SG188591A1 (en) 2010-09-22 2013-04-30 Amgen Inc Carrier immunoglobulins and uses thereof
MX346995B (es) 2010-12-15 2017-04-06 Wyeth Llc Anticuerpos anti-notch1.
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (fr) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Anticorps dirigés contre les angiopoïétines 1 et 2, et leur utilisation
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2714937B1 (fr) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
BR112014006822B1 (pt) 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
EP2761008A1 (fr) 2011-09-26 2014-08-06 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
EP2760471B9 (fr) 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
CA2850830A1 (fr) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methodes de traitement du syndrome de fuite vasculaire et du cancer
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2861610A1 (fr) 2011-12-30 2013-07-04 Abbvie Inc. Proteines a double liaison specifique dirigees contre l'il-13 et/ou l'il-17
WO2013112438A1 (fr) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Formulations stabilisées contenant des anticorps anti-ang2
JO3547B1 (ar) 2012-01-31 2020-07-05 Regeneron Pharma أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
AU2013230750B2 (en) 2012-03-08 2018-02-01 Medimmune, Llc Methods of treatment with Angiopoietin-2 antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
HUE044263T2 (hu) 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
SG11201406855TA (en) 2012-04-27 2014-11-27 Millennium Pharm Inc Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014001325A1 (fr) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Méthode de fabrication de conjugués d'anticorps à région fc comprenant au moins une entité de liaison qui se lie spécifiquement à une cible et leurs utilisations
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
IL282082B (en) 2012-08-23 2022-08-01 Seagen Inc Antibody-drug conjugates (adc) binding to 158p1d7 proteins
CN104768575B (zh) * 2012-08-31 2017-09-08 国立大学法人大阪大学 含有vegf特异性表位和/或血管生成素‑2特异性表位的dna疫苗
DK2890836T3 (da) * 2012-08-31 2019-09-16 Scripps Research Inst Fremgangsmåder i forbindelse med modulatorer af eukaryotiske celler
KR101967345B1 (ko) 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
JP6326066B2 (ja) * 2012-12-20 2018-05-16 メディミューン，エルエルシー 凝集プロファイルが改善されている液状抗体製剤
WO2014108854A1 (fr) 2013-01-09 2014-07-17 Fusimab Ltd. Anticorps anti-hgf et anti-ang2 monospécifiques, et anticorps anti-hgf/anti-ang2 bispécifiques
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
EP3424530A1 (fr) 2013-03-15 2019-01-09 Zyngenia, Inc. Complexes multispécifiques monovalents et multivalents et leurs utilisations
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
US10745483B2 (en) 2013-03-15 2020-08-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
EP2787006B1 (fr) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anticorps anti-CD8 dont la liaison dépend de Ca2+
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
JP6411379B2 (ja) * 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
CN103333247B (zh) * 2013-05-30 2014-10-08 北京东方百泰生物科技有限公司 新型抗vegfr2的单克隆抗体及其制备与应用
KR102131371B1 (ko) * 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
EP2835380B2 (fr) * 2013-07-29 2021-04-07 Samsung Electronics Co., Ltd Procédé de blocage de fuite vasculaire utilisant un anticorps anti-ANG2
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) * 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
US10279021B2 (en) 2014-03-14 2019-05-07 Dana-Faber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
CA3104268A1 (fr) * 2014-04-10 2015-10-15 Obi Pharma Inc. Anticorps, compositions pharmaceutiques et leurs utilisations
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6946184B2 (ja) * 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
WO2016087416A1 (fr) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (fr) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
WO2016176427A1 (fr) 2015-04-30 2016-11-03 Amgen Inc. Traitement du cancer de l'ovaire chez les patientes souffrant d'ascite au moyen d'un agent de fixation spécifique de l'angiopoïétine-2 humaine combiné à un taxane
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
ES2828694T3 (es) * 2015-07-29 2021-05-27 Allergan Inc Anticuerpos sólo de cadena pesada frente a ANG-2
WO2017023780A1 (fr) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugués anticorps-médicament destinés à être utilisés pour cibler des tumeurs cd56+
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
MA42843A (fr) 2015-09-16 2018-07-25 Ablexis Llc Anticorps anti-cd115
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
EP3184547A1 (fr) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anticorps anti-tpbg et procédés d'utilisation
PL3373968T3 (pl) * 2015-11-09 2024-08-05 The Children's Hospital Of Philadelphia Glipikan 2 jako marker nowotworowy i cel terapeutyczny
CN108366968B (zh) 2015-12-16 2022-02-18 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017127468A1 (fr) * 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anticorps anti-facteur xi de coagulation
EP3445783A2 (fr) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Anticorps agonistes se liant au cd40 humain et leurs utilisations
EP3472622B1 (fr) * 2016-06-17 2020-08-05 Roche Diagnostics GmbH Circulation d'angiopoiétine-2 (ang-2) pour la prédiction de la récurrence de fibrillation auriculaire
SG11201900200XA (en) * 2016-07-14 2019-02-27 Scholar Rock Inc Tgfb antibodies, methods, and uses
WO2018017964A2 (fr) * 2016-07-21 2018-01-25 Emory University Anticorps contre le virus ebola et agents de liaison dérivés de ceux-ci
AU2017315075B2 (en) * 2016-08-23 2020-10-01 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
CN106866824B (zh) * 2017-03-06 2020-10-27 哈尔滨医科大学 一种抗ddx5的全人源单克隆抗体及其制备方法和应用
CN109022415B (zh) * 2017-06-12 2023-09-15 上海睿智化学研究有限公司 PDGFRβ单克隆重链抗体杂交瘤细胞及其制备方法和应用
EP3661536A4 (fr) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. Procédés d'identification et de préparation d'agents pharmaceutiques pour activer le récepteur tie2
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
WO2019084307A1 (fr) * 2017-10-26 2019-05-02 Celldex Therapeutics, Inc. Anticorps anti-mertk et leurs procédés d'utilisation
CN111630063A (zh) * 2018-01-31 2020-09-04 豪夫迈·罗氏有限公司 稳定化的免疫球蛋白结构域
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
MX2020010227A (es) * 2018-03-30 2021-02-17 Eureka Therapeutics Inc Construcciones dirigidas a cd22 y usos de las mismas.
MA52202A (fr) 2018-04-02 2021-02-17 Amgen Inc Compositions d'érénumab et utilisations de celles-ci
EP3880714A4 (fr) * 2018-11-16 2022-07-20 Memorial Sloan Kettering Cancer Center Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
AU2020227580A1 (en) * 2019-02-25 2021-09-30 Pharmabcine Inc. Anti-Ang2 antibody and use thereof
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
CA3139507A1 (fr) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior Unversity Recepteurs antigeniques chimeriques ciblant le glypicane-2
CN112062848B (zh) * 2019-06-10 2022-06-17 山东博安生物技术股份有限公司 抗cd47单克隆抗体及其应用
JP2022539527A (ja) * 2019-06-26 2022-09-12 エーピー バイオサイエンシーズ， インコーポレイテッド Ｔ細胞活性化のための抗体
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
JP2023530187A (ja) * 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
EP4190813A1 (fr) * 2020-07-31 2023-06-07 Bio-Thera Solutions, Ltd. Anticorps contre le cd47 et son application
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
WO2022226539A1 (fr) * 2021-04-23 2022-10-27 Immunome, Inc. Méthodes d'administration d'anticorps contre la protéine de spicule du sars-cov-2
WO2023192990A2 (fr) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Anticorps contre le siglec-9 humain et leur utilisation pour l'immunothérapie
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1A1 (ru) 1921-03-25 1924-09-15 А.М. Настюков Печь дл непрерывного получени сернистого натри
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0052322B1 (fr) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Méthode de préparation de vésicules lipidiques par traitement aux ultra-sons, utilisation de ce procédé et l'appareillage ainsi utilisé
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (fr) 1991-06-12 1992-12-23 Genpharm International, Inc. Detection precoce d'embryons transgeniques
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
CA2135313A1 (fr) 1992-06-18 1994-01-06 Theodore Choi Methodes pour l'obtention d'animaux transgeniques, comportant un chromosome artificiel de levure
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
DE69633121T2 (de) 1995-04-06 2005-07-28 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19525542A1 (de) 1995-07-13 1997-01-16 Mann & Hummel Filter Heizeinrichtung
DE69636868T2 (de) 1995-08-29 2007-10-25 Kirin Beer Kabushiki Kaisha Chimäres tier und methode zu dessen herstellung
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
PT1520588E (pt) 1998-07-13 2015-03-31 Univ Texas Usos de anticorpos para amino fosfolípidos para o tratamento do cancro
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
CA2368670C (fr) 1999-03-26 2012-06-05 Chitra Suri Modulation de la permeabilite vasculaire au moyen d'activateurs de recepteurs tie2
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
CA2372053C (fr) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions et procedes de traitement du cancer par inhibition selective de vegf
NZ516258A (en) * 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1130094A3 (fr) 1999-07-08 2001-11-21 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation
AU782728B2 (en) 1999-08-19 2005-08-25 Serono Genetics Institute S.A. Prostate cancer-relased gene 3 (PG-3) and biallelic markers thereof
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
WO2001073027A2 (fr) 2000-03-24 2001-10-04 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US7642278B2 (en) 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2002353017A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Discovery of therapeutic products
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
DE102004062018B4 (de) 2004-12-23 2018-10-11 Robert Bosch Gmbh Verfahren zum Betreiben einer Brennkraftmaschine
JP5374359B2 (ja) 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
KR101136303B1 (ko) 2008-01-28 2012-04-24 리서치 인 모션 리미티드 세션 개시 프로토콜 요청 컨텐츠를 제공하는 방법 및 시스템
CA2712000A1 (fr) * 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilises contre l'angiopoietine-2 et leurs utilisations
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
CY1112909T1 (el) 2016-04-13
ZA200705695B (en) 2009-02-25
WO2006068953A3 (fr) 2007-08-02
RS52036B (en) 2012-04-30
TW200634027A (en) 2006-10-01
NO20073192L (no) 2007-09-06
NZ556029A (en) 2010-04-30
PL1838733T3 (pl) 2012-02-29
US20150125455A1 (en) 2015-05-07
RU2007127842A (ru) 2009-01-27
JP2012050455A (ja) 2012-03-15
HRP20110859T1 (hr) 2011-12-31
KR101017301B1 (ko) 2011-02-28
KR20070116217A (ko) 2007-12-07
BRPI0519596A2 (pt) 2009-03-24
CN101128483B (zh) 2015-06-03
CA2595610A1 (fr) 2006-06-29
ES2371083T3 (es) 2011-12-27
BRPI0519596B1 (pt) 2022-01-18
JP4884395B2 (ja) 2012-02-29
EP2284194A1 (fr) 2011-02-16
AU2005319382A1 (en) 2006-06-29
CA2595610C (fr) 2013-03-05
CN105085678A (zh) 2015-11-25
US20120052073A1 (en) 2012-03-01
JP5642042B2 (ja) 2014-12-17
US8834880B2 (en) 2014-09-16
JP2008523841A (ja) 2008-07-10
PT1838733E (pt) 2011-12-13
US10066011B2 (en) 2018-09-04
CN105085678B (zh) 2019-05-07
WO2006068953A2 (fr) 2006-06-29
US20060246071A1 (en) 2006-11-02
EP1838733A2 (fr) 2007-10-03
EP1838733B1 (fr) 2011-08-24
HK1217713A1 (zh) 2017-01-20
US7973140B2 (en) 2011-07-05
SI1838733T1 (sl) 2011-12-30
DK1838733T3 (da) 2011-11-28
EP3699191A1 (fr) 2020-08-26
US20130171160A1 (en) 2013-07-04
RU2394839C2 (ru) 2010-07-20
MX2007007484A (es) 2007-07-20
ATE521638T1 (de) 2011-09-15
UY29288A1 (es) 2006-07-31
AR052065A1 (es) 2007-02-28
CN101128483A (zh) 2008-02-20
AU2005319382B2 (en) 2011-04-07
US20080267971A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
HK1217713A1 (zh) 血管生成素- 的抗體及其應用
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
HK1173158A1 (en) Antibodies directed to her-3 and uses thereof her-3
HRP20140271T1 (hr) Humana antitijela protiv bjesnoä†e i njihova uporaba
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL222922A (en) Antibodies against neurophilin-1 and their use
ZA200608100B (en) IRTA-5 antibodies and their uses
HK1120273A1 (zh) 抗體及其使用方法
IL188088A0 (en) Cd19 antibodies and their uses
IL178356A0 (en) Dr5 antibodies and uses thereof
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL187784A0 (en) Antibodies directed to cd20 and uses thereof
IL184024A0 (en) Irta-5 antibodies and their uses
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
ZA200710916B (en) CD19 antibodies and their uses
ZA200702281B (en) IRTA-4 antibodies and their uses
ZA200705716B (en) IRTA-2 antibodies and their uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211219